Tyrosine kinase update: Role and response in cancer therapy

Rosalyn Irby, Yixing Jiang

Research output: Contribution to journalArticle

Abstract

For the past several decades, the understanding of the molecular mechanisms of cancer initiation, progression, and metastasis has increased. As data elucidating these mechanisms has been amassed, potential targets for therapy have been identified. Tyrosine kinases were first recognized in 1979 and subsequently their potential role in cancer has been established. There are approximately 90 known tyrosine kinases in human cells, about half of which are receptor tyrosine kinases. The receptor tyrosine kinases span the cell membrane and are activated by binding of a ligand. Cytoplasmic nonreceptor tyrosine kinases, or intracellular tyrosine kinases, are downstream of receptor tyrosine kinases. The receptor tyrosine kinases act in concert with intracellular tyrosine kinases to mediate cell behaviors, including growth and proliferation, angiogenesis, apoptosis, gene transcription, and intercellular interactions. Inappropriate activation of tyrosine kinases plays a significant role in the initiation and progression of human cancers. The critical role of tyrosine kinases in signal transduction, coupled with the frequent incidence of their increased expression levels and activating gene mutations in cancer, makes these enzymes attractive targets for therapeutic intervention in cancer treatment. This article provides a summary of current drugs targeting tyrosine kinases for cancer therapy, focusing on those being used in the clinic.

Original languageEnglish (US)
Pages (from-to)155-166
Number of pages12
JournalCurrent Cancer Therapy Reviews
Volume7
Issue number2
StatePublished - May 1 2011

Fingerprint

Protein-Tyrosine Kinases
Receptor Protein-Tyrosine Kinases
Neoplasms
Therapeutics
Drug Delivery Systems
Genes
Signal Transduction
Cell Membrane
Apoptosis
Neoplasm Metastasis
Ligands
Mutation
Incidence
Enzymes
Growth

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

@article{4cb2e8749147461481c88b1c7ec5d622,
title = "Tyrosine kinase update: Role and response in cancer therapy",
abstract = "For the past several decades, the understanding of the molecular mechanisms of cancer initiation, progression, and metastasis has increased. As data elucidating these mechanisms has been amassed, potential targets for therapy have been identified. Tyrosine kinases were first recognized in 1979 and subsequently their potential role in cancer has been established. There are approximately 90 known tyrosine kinases in human cells, about half of which are receptor tyrosine kinases. The receptor tyrosine kinases span the cell membrane and are activated by binding of a ligand. Cytoplasmic nonreceptor tyrosine kinases, or intracellular tyrosine kinases, are downstream of receptor tyrosine kinases. The receptor tyrosine kinases act in concert with intracellular tyrosine kinases to mediate cell behaviors, including growth and proliferation, angiogenesis, apoptosis, gene transcription, and intercellular interactions. Inappropriate activation of tyrosine kinases plays a significant role in the initiation and progression of human cancers. The critical role of tyrosine kinases in signal transduction, coupled with the frequent incidence of their increased expression levels and activating gene mutations in cancer, makes these enzymes attractive targets for therapeutic intervention in cancer treatment. This article provides a summary of current drugs targeting tyrosine kinases for cancer therapy, focusing on those being used in the clinic.",
author = "Rosalyn Irby and Yixing Jiang",
year = "2011",
month = "5",
day = "1",
language = "English (US)",
volume = "7",
pages = "155--166",
journal = "Current Cancer Therapy Reviews",
issn = "1573-3947",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

Tyrosine kinase update : Role and response in cancer therapy. / Irby, Rosalyn; Jiang, Yixing.

In: Current Cancer Therapy Reviews, Vol. 7, No. 2, 01.05.2011, p. 155-166.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tyrosine kinase update

T2 - Role and response in cancer therapy

AU - Irby, Rosalyn

AU - Jiang, Yixing

PY - 2011/5/1

Y1 - 2011/5/1

N2 - For the past several decades, the understanding of the molecular mechanisms of cancer initiation, progression, and metastasis has increased. As data elucidating these mechanisms has been amassed, potential targets for therapy have been identified. Tyrosine kinases were first recognized in 1979 and subsequently their potential role in cancer has been established. There are approximately 90 known tyrosine kinases in human cells, about half of which are receptor tyrosine kinases. The receptor tyrosine kinases span the cell membrane and are activated by binding of a ligand. Cytoplasmic nonreceptor tyrosine kinases, or intracellular tyrosine kinases, are downstream of receptor tyrosine kinases. The receptor tyrosine kinases act in concert with intracellular tyrosine kinases to mediate cell behaviors, including growth and proliferation, angiogenesis, apoptosis, gene transcription, and intercellular interactions. Inappropriate activation of tyrosine kinases plays a significant role in the initiation and progression of human cancers. The critical role of tyrosine kinases in signal transduction, coupled with the frequent incidence of their increased expression levels and activating gene mutations in cancer, makes these enzymes attractive targets for therapeutic intervention in cancer treatment. This article provides a summary of current drugs targeting tyrosine kinases for cancer therapy, focusing on those being used in the clinic.

AB - For the past several decades, the understanding of the molecular mechanisms of cancer initiation, progression, and metastasis has increased. As data elucidating these mechanisms has been amassed, potential targets for therapy have been identified. Tyrosine kinases were first recognized in 1979 and subsequently their potential role in cancer has been established. There are approximately 90 known tyrosine kinases in human cells, about half of which are receptor tyrosine kinases. The receptor tyrosine kinases span the cell membrane and are activated by binding of a ligand. Cytoplasmic nonreceptor tyrosine kinases, or intracellular tyrosine kinases, are downstream of receptor tyrosine kinases. The receptor tyrosine kinases act in concert with intracellular tyrosine kinases to mediate cell behaviors, including growth and proliferation, angiogenesis, apoptosis, gene transcription, and intercellular interactions. Inappropriate activation of tyrosine kinases plays a significant role in the initiation and progression of human cancers. The critical role of tyrosine kinases in signal transduction, coupled with the frequent incidence of their increased expression levels and activating gene mutations in cancer, makes these enzymes attractive targets for therapeutic intervention in cancer treatment. This article provides a summary of current drugs targeting tyrosine kinases for cancer therapy, focusing on those being used in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=79953798975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953798975&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79953798975

VL - 7

SP - 155

EP - 166

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

SN - 1573-3947

IS - 2

ER -